Kadimastem Company

Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin secreting beta cells as well as a range of neural cells, including Oligodendrocytes and Astrocytes. Based on its differentiation technologies, the company advances two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells for the diabetes program and astrocytes for the ALS program, with the goal of implanting them into patients, and affecting diseases progression. The company’s technology is designed to screen compounds automatically and quantify the readouts using a cell-based High Content Screening (HCS) system. Kadimastem partners with pharmaceutical companies to screen potential drug compounds on its stem-cell derived cells.
Technology: Biotechnology, Therapeutics
Industry: Regenerative Medicine
Headquarters: Ness Ziona, Israel
Founded Date: 11-50
Employees Number: 2009
Funding Status: IPO

Visit Website
info@kadimastem.com
twitter.com/kadimastemltd
Register and Claim Ownership